A randomized controlled trial of diet and physical activity in BRCA mutation carriers
- 27 October 2013
- journal article
- research article
- Published by Springer Nature in Familial Cancer
- Vol. 13 (2) , 181-187
Abstract
High serum levels of insulin-like growth factor I (IGF-I) are associated with an increased risk of sporadic breast cancer (BC). Furthermore, insulin and markers of insulin resistance, such as abdominal obesity, high blood glucose, high serum testosterone and metabolic syndrome, may affect both BC incidence and prognosis. We hypothesized that all these factors might be relevant also for hereditary BC, due to a deleterious mutation of BRCA genes. Epidemiological observation suggested that weight, energy intake (usually associated with higher bio-availability of growth factors) and physical activity may be relevant in BRCA mutation carriers. Mechanistic studies hypothesized a functional interaction between BRCA genes and the IGF-I system. We have provided some evidence that high serum levels of IGF-I are associated with a significantly increased penetrance. We are recruiting a larger cohort of BRCA mutation carriers in order to test potential modulators of penetrance and prognosis. Within this cohort, we have planned a randomized controlled trial to test whether moderate calorie and protein restriction, together with physical activity, decrease IGF-I. Eligible study subjects are women with or without BC, aged 18–70, with a proven deleterious BRCA mutation, and without metastases. All the women will receive recommendations for the dietary prevention of cancer. The women will be then randomized into an active life-style intervention group and into a control group that will receive only the baseline recommendations. We expect to significantly reduce IGF-I in the intervention group. This trial and the subsequent cohort follow-up might open up primary prevention options for genetic BC.Keywords
This publication has 34 references indexed in Scilit:
- A prospective investigation of predictive and modifiable risk factors for breast cancer in unaffected BRCA1 and BRCA2gene carriersBMC Cancer, 2013
- IGF-1 and BRCA1 signalling pathways in familial cancerThe Lancet Oncology, 2012
- Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studiesThe Lancet Oncology, 2010
- Elevated insulin-like growth factor-I receptor (IGF-IR) levels in primary breast tumors associated with BRCA1 mutationsCancer Letters, 2007
- Insulin-like Growth Factor-I Controls BRCA1 Gene Expression through Activation of Transcription Factor Sp1Hormone and Metabolic Research, 2007
- Diet, serum insulin-like growth factor-I and IGF-binding protein-3 in European womenEuropean Journal of Clinical Nutrition, 2006
- Cancer Risk Estimates for BRCA1 Mutation Carriers Identified in a Risk Evaluation ProgramJNCI: Journal of the National Cancer Institute, 2002
- Reducing bioavailable sex hormones through a comprehensive change in diet: the diet and androgens (DIANA) randomized trial.2001
- Cancer Risks in BRCA2 Mutation CarriersJNCI: Journal of the National Cancer Institute, 1999
- Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium.1993